Charles L. Sentman - Publications

Affiliations: 
Immunology and Microbiology Dartmouth College, Hanover, NH, United States 
Area:
Cell Biology, Molecular Biology

70 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Godbersen-Palmer C, Coupet TA, Grada Z, Zhang SC, Sentman CL. Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice. Journal of Immunology (Baltimore, Md. : 1950). PMID 32295875 DOI: 10.4049/jimmunol.1901401  0.6
2018 Murad JM, Baumeister SH, Werner L, Daley H, Trébéden-Negre H, Reder J, Sentman CL, Gilham D, Lehmann F, Snykers S, Sentman ML, Wade T, Schmucker A, Fanger MW, Dranoff G, et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Cytotherapy. 20: 952-963. PMID 30180944 DOI: 10.1016/j.jcyt.2018.05.001  0.8
2018 Gacerez AT, Sentman CL. T-bet promotes potent antitumor activity of CD4CAR T cells. Cancer Gene Therapy. PMID 29515240 DOI: 10.1038/s41417-018-0012-7  0.6
2018 Gacerez AT, Hua CK, Ackerman ME, Sentman CL. Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression. Cancer Immunology, Immunotherapy : Cii. PMID 29453518 DOI: 10.1007/s00262-018-2124-1  0.6
2017 Hua CK, Gacerez AT, Sentman CL, Ackerman ME, Choi Y, Bailey-Kellogg C. Computationally-driven identification of antibody epitopes. Elife. 6. PMID 29199956 DOI: 10.7554/eLife.29023  0.6
2017 Hua CK, Gacerez AT, Sentman CL, Ackerman ME. Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6. Protein Engineering, Design & Selection : Peds. 1-9. PMID 29040754 DOI: 10.1093/protein/gzx051  0.6
2017 Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S. Exploiting natural killer group 2D receptors for CAR T-cell therapy. Future Oncology (London, England). PMID 28613086 DOI: 10.2217/fon-2017-0102  0.8
2017 Godbersen C, Coupet TA, Huehls AM, Zhang T, Battles MB, Fisher JL, Ernstoff MS, Sentman CL. NKG2D ligand targeted Bispecific T Cell Engagers lead to robust antitumor activity against diverse human tumors. Molecular Cancer Therapeutics. PMID 28500232 DOI: 10.1158/1535-7163.MCT-16-0846  0.6
2016 Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, Dranoff G, Fanger MW, Sentman CL. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. Journal of Immunology (Baltimore, Md. : 1950). PMID 27849169 DOI: 10.4049/jimmunol.1600769  0.8
2016 Smits NC, Coupet TA, Godbersen C, Sentman CL. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer. Expert Opinion On Biological Therapy. PMID 27248342 DOI: 10.1080/14712598.2016.1195364  0.6
2016 Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S. Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy. Frontiers in Immunology. 7: 176. PMID 27242783 DOI: 10.3389/fimmu.2016.00176  1
2016 Gacerez AT, Arellano B, Sentman CL. How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. Journal of Cellular Physiology. PMID 27163336 DOI: 10.1002/jcp.25419  0.6
2015 Gowen BG, Chim B, Marceau CD, Greene TT, Burr P, Gonzalez JR, Hesser CR, Dietzen PA, Russell T, Iannello A, Coscoy L, Sentman CL, Carette JE, Muljo SA, Raulet DH. A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. Elife. 4. PMID 26565589 DOI: 10.7554/eLife.08474  1
2015 Choi Y, Hua C, Sentman CL, Ackerman ME, Bailey-Kellogg C. Antibody humanization by structure-based computational protein design. Mabs. 7: 1045-57. PMID 26252731 DOI: 10.1080/19420862.2015.1076600  1
2015 Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR, Sentman CL. B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity. Journal of Immunology (Baltimore, Md. : 1950). 194: 5305-11. PMID 25911747 DOI: 10.4049/jimmunol.1402517  0.8
2015 Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Therapy. PMID 25830550 DOI: 10.1038/gt.2015.29  0.8
2015 Wu MR, Zhang T, Alcon A, Sentman CL. DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. Cancer Immunology, Immunotherapy : Cii. 64: 409-18. PMID 25549845 DOI: 10.1007/s00262-014-1648-2  0.8
2015 Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunology and Cell Biology. 93: 290-6. PMID 25367186 DOI: 10.1038/icb.2014.93  0.6
2014 Wu MR, Cook WJ, Zhang T, Sentman CL. Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles. Nanotechnology. 25: 475101. PMID 25371538 DOI: 10.1088/0957-4484/25/47/475101  0.8
2014 Sentman CL, Meehan KR. NKG2D CARs as cell therapy for cancer. Cancer Journal (Sudbury, Mass.). 20: 156-9. PMID 24667963 DOI: 10.1097/PPO.0000000000000029  0.48
2014 Talebian L, Fischer DA, Wu J, Channon JY, Sentman CL, Ernstoff MS, Meehan KR. The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells. Transfusion. 54: 1515-21. PMID 24446786 DOI: 10.1111/trf.12517  1
2013 Spear P, Wu MR, Sentman ML, Sentman CL. NKG2D ligands as therapeutic targets. Cancer Immunity. 13: 8. PMID 23833565  1
2013 Spear P, Barber A, Sentman CL. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology. 2: e23564. PMID 23734311 DOI: 10.4161/onci.23564  1
2013 Spear P, Barber A, Rynda-Apple A, Sentman CL. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunology and Cell Biology. 91: 435-40. PMID 23628805 DOI: 10.1038/icb.2013.17  1
2013 Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 2455-63. PMID 23355740 DOI: 10.4049/jimmunol.1201314  0.6
2013 Meehan KR, Talebian L, Tosteson TD, Hill JM, Szczepiorkowski Z, Sentman CL, Ernstoff MS. Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 129-37. PMID 22975165 DOI: 10.1016/j.bbmt.2012.08.018  1
2012 Zhang T, Wu MR, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. Journal of Immunology (Baltimore, Md. : 1950). 189: 2290-9. PMID 22851709 DOI: 10.4049/jimmunol.1103495  0.8
2012 Spear P, Barber A, Rynda-Apple A, Sentman CL. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. Journal of Immunology (Baltimore, Md. : 1950). 188: 6389-98. PMID 22586039 DOI: 10.4049/jimmunol.1103019  1
2011 Iyori M, Zhang T, Pantel H, Gagne BA, Sentman CL. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells. Journal of Immunology (Baltimore, Md. : 1950). 187: 3087-95. PMID 21832159 DOI: 10.4049/jimmunol.1003879  0.6
2011 Talebian L, Wu JY, Fischer DA, Hill JM, Szczepiorkowski ZM, Ernstoff MS, Sentman CL, Meehan KR. Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma. Frontiers in Bioscience (Elite Edition). 3: 1500-8. PMID 21622154  1
2011 Barber A, Sentman CL. NKG2D receptor regulates human effector T-cell cytokine production. Blood. 117: 6571-81. PMID 21518928 DOI: 10.1182/blood-2011-01-329417  1
2011 Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Research. 71: 2066-76. PMID 21282338 DOI: 10.1158/0008-5472.CAN-10-3200  0.6
2011 Barber A, Meehan KR, Sentman CL. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Therapy. 18: 509-16. PMID 21209626 DOI: 10.1038/gt.2010.174  1
2010 Meehan KR, Talebian L, Wu J, Hill JM, Szczepiorkowski ZM, Sentman CL, Ernstoff MS. Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. Cytotherapy. 12: 1013-21. PMID 20873991 DOI: 10.3109/14653249.2010.515580  0.48
2010 Kopcow HD, Eriksson M, Mselle TF, Damrauer SM, Wira CR, Sentman CL, Strominger JL. Human decidual NK cells from gravid uteri and NK cells from cycling endometrium are distinct NK cell subsets. Placenta. 31: 334-8. PMID 20172608 DOI: 10.1016/j.placenta.2010.01.003  1
2009 Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. Journal of Immunology (Baltimore, Md. : 1950). 183: 6939-47. PMID 19915047 DOI: 10.4049/jimmunol.0902000  1
2009 Mselle TF, Howell AL, Ghosh M, Wira CR, Sentman CL. Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12. Journal of Virology. 83: 11188-95. PMID 19692460 DOI: 10.1128/JVI.00562-09  1
2009 Barber A, Sentman CL. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. Journal of Immunology (Baltimore, Md. : 1950). 183: 2365-72. PMID 19625653 DOI: 10.4049/jimmunol.0900721  1
2009 Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. The Journal of Clinical Investigation. 119: 2231-44. PMID 19620771 DOI: 10.1172/JCI37716  1
2009 Kalkunte SS, Mselle TF, Norris WE, Wira CR, Sentman CL, Sharma S. Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. Journal of Immunology (Baltimore, Md. : 1950). 182: 4085-92. PMID 19299706 DOI: 10.4049/jimmunol.0803769  1
2009 Basu S, Eriksson M, Pioli PA, Conejo-Garcia J, Mselle TF, Yamamoto S, Wira CR, Sentman CL. Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 61: 52-61. PMID 19086992 DOI: 10.1111/j.1600-0897.2008.00661.x  1
2008 Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Research. 68: 7684-91. PMID 18768667 DOI: 10.1158/0008-5472.CAN-08-1167  1
2008 Basu S, Pioli PA, Conejo-Garcia J, Wira CR, Sentman CL. Estradiol regulates MICA expression in human endometrial cells. Clinical Immunology (Orlando, Fla.). 129: 325-32. PMID 18728002 DOI: 10.1016/j.clim.2008.07.005  1
2008 Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Experimental Hematology. 36: 1318-28. PMID 18599182 DOI: 10.1016/j.exphem.2008.04.010  1
2008 Kalkunte S, Chichester CO, Gotsch F, Sentman CL, Romero R, Sharma S. Evolution of non-cytotoxic uterine natural killer cells. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 59: 425-32. PMID 18405313 DOI: 10.1111/j.1600-0897.2008.00595.x  1
2008 Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. Journal of Immunology (Baltimore, Md. : 1950). 180: 72-8. PMID 18097006  1
2008 Barber MA, Zhang T, Gagne BA, Van Ginderachter JA, De Baetselier P, Sentman CL. Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model. Cancer Immunology, Immunotherapy : Cii. 57: 655-62. PMID 17891395 DOI: 10.1007/s00262-007-0404-2  0.6
2007 Zhang T, Barber A, Sentman CL. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Research. 67: 11029-36. PMID 18006849 DOI: 10.1158/0008-5472.CAN-07-2251  1
2007 Mselle TF, Meadows SK, Eriksson M, Smith JM, Shen L, Wira CR, Sentman CL. Unique characteristics of NK cells throughout the human female reproductive tract. Clinical Immunology (Orlando, Fla.). 124: 69-76. PMID 17524808 DOI: 10.1016/j.clim.2007.04.008  1
2007 Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Research. 67: 5003-8. PMID 17510432 DOI: 10.1158/0008-5472.CAN-06-4047  1
2007 Barber MA, Zhang T, Gagne BA, Sentman CL. NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. Journal of Immunology (Baltimore, Md. : 1950). 178: 6140-7. PMID 17475840  0.6
2007 Shen L, Smith JM, Shen Z, Eriksson M, Sentman C, Wira CR. Inhibition of human neutrophil degranulation by transforming growth factor-β1 Clinical and Experimental Immunology. 149: 155-161. PMID 17403059 DOI: 10.1111/j.1365-2249.2007.03376.x  1
2007 Sentman CL, Wira CR, Eriksson M. NK cell function in the human female reproductive tract. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 57: 108-15. PMID 17217364 DOI: 10.1111/j.1600-0897.2006.00448.x  1
2007 Grundy MA, Zhang T, Sentman CL. NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. Cancer Immunology, Immunotherapy : Cii. 56: 1153-61. PMID 17160409 DOI: 10.1007/s00262-006-0264-1  0.6
2006 Eriksson M, Meadows SK, Wira CR, Sentman CL. Endogenous transforming growth factor-beta inhibits toll-like receptor mediated activation of human uterine natural killer cells. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 56: 321-8. PMID 17076676 DOI: 10.1111/j.1600-0897.2006.00432.x  1
2006 Sentman CL, Barber MA, Barber A, Zhang T. NK cell receptors as tools in cancer immunotherapy. Advances in Cancer Research. 95: 249-92. PMID 16860660 DOI: 10.1016/S0065-230X(06)95007-6  1
2006 Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Research. 66: 5927-33. PMID 16740733 DOI: 10.1158/0008-5472.CAN-06-0130  1
2006 Eriksson M, Meadows SK, Basu S, Mselle TF, Wira CR, Sentman CL. TLRs mediate IFN-gamma production by human uterine NK cells in endometrium. Journal of Immunology (Baltimore, Md. : 1950). 176: 6219-24. PMID 16670332 DOI: 10.4049/jimmunol.176.10.6219  1
2006 Meadows SK, Eriksson M, Barber A, Sentman CL. Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. International Immunopharmacology. 6: 1020-8. PMID 16644489 DOI: 10.1016/j.intimp.2006.01.013  1
2005 Usherwood EJ, Meadows SK, Crist SG, Bellfy SC, Sentman CL. Control of murine gammaherpesvirus infection is independent of NK cells. European Journal of Immunology. 35: 2956-61. PMID 16134085 DOI: 10.1002/eji.200526245  1
2005 Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunological Reviews. 206: 306-35. PMID 16048557 DOI: 10.1111/j.0105-2896.2005.00287.x  1
2005 Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 106: 1544-51. PMID 15890688 DOI: 10.1182/blood-2004-11-4365  0.6
2004 Sentman CL, Meadows SK, Wira CR, Eriksson M. Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. Journal of Immunology (Baltimore, Md. : 1950). 173: 6760-6. PMID 15557169  1
2004 Eriksson M, Meadows SK, Wira CR, Sentman CL. Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-beta. Journal of Leukocyte Biology. 76: 667-75. PMID 15178706 DOI: 10.1189/jlb.0204090  1
2000 Fahlén L, Oberg L, Brännström T, Khoo NK, Lendahl U, Sentman CL. Ly49A expression on T cells alters T cell selection. International Immunology. 12: 215-22. PMID 10653857 DOI: 10.1093/intimm/12.2.215  1
1999 Daws MR, Eriksson M, Oberg L, Ullén A, Sentman CL. H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1. Immunology. 97: 656-64. PMID 10457220 DOI: 10.1046/j.1365-2567.1999.00825.x  0.48
1999 Achour A, Harris RA, Persson K, Sundbäck J, Sentman CL, Schneider G, Lindqvist Y, Kärre K. Murine class I major histocompatibility complex H-2D(d): Expression, refolding and crystallization Acta Crystallographica Section D: Biological Crystallography. 55: 260-262. PMID 10089418  1
1998 Khoo NKS, Fahlén L, Sentman CL. Modulation of Ly49A receptors on mature cells to changes in major histocompatibility complex class I molecules Immunology. 95: 126-131. PMID 9767467 DOI: 10.1046/j.1365-2567.1998.00577.x  1
1998 Achour A, Persson K, Harris RA, Sundbäck J, Sentman CL, Lindqvist Y, Schneides G, Kärre K. The crystal structure of H-2D(d) MHC class I complexed with the HIV-1- derived peptide P18-110 at 2.4 Å resolution: Implications for T cell and NK cell recognition Immunity. 9: 199-208. PMID 9729040  1
1997 Fahlén L, Khoo NKS, Daws MR, Sentman CL. Location-specific regulation of transgenic Ly49A receptors by major histocompatibility complex class I molecules European Journal of Immunology. 27: 2057-2065. PMID 9295045 DOI: 10.1002/eji.1830270833  1
Show low-probability matches.